Insight Molecular DiagnosticsvsJohnson & Johnson

IMDX and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

IMDX

Insight Molecular Diagnostics Inc.

$1.97

Value $63M

+18.67%
IMDX's page

Insight Molecular Diagnostics (IMDX) has a market value of $63M and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, IMDX moved -67.2% and JNJ +36.6%. Dividend yield: IMDX none, JNJ 1.95%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    IMDX$63M

    JNJ$652B

    JNJ is 10,286 times IMDX

  • Revenue, 12 months

    IMDX$2.0M

    JNJ$99.3B

    JNJ is 50,449 times IMDX

  • Net income, 12 months

    IMDX-$42M

    JNJ$16.1B

  • Operating margin

    IMDX-2,180.1%

    JNJ–

  • ROIC

    IMDX–

    JNJ12.4%

  • P/E

    IMDX–

    JNJ40.5

  • Dividend yield

    IMDX0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    IMDX-96.4%

    JNJ+90.9%

    187.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

IMDX-96.4%

JNJ+90.9%

010020020222023202420252026
Returns by period
PeriodIMDXWith dividendsJNJWith dividends
1 year since November 19, 2025-67.2%Price -67.2%+36.6%Price +33.6%
3 years since November 20, 2023-50.3%-20.8% a yearPrice -50.3%+94.9%+24.9% a yearPrice +80.4%
5 years since November 19, 2021-96.4%-48.7% a yearPrice -96.4%+90.9%+13.8% a yearPrice +66.0%
10 years since November 22, 2016-98.3%-33.4% a yearPrice -98.3%+212.6%+12.1% a yearPrice +139.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

IMDXInsight Molecular DiagnosticsJNJJohnson & Johnson

Valuation

IMDXJNJ
Valuation
Price$1.97$270.47
Market value$63M$652B
Enterprise value (EV)$53M$679B
P/E–40.5
P/E, 5-year median–21.9
P/B–8.0
EV/EBIT–38.3
Free cash flow yield–3.2%

Results and growth

IMDXJNJ
Results and growth
Revenue, 12 months$2.0M$99.3B
Net income, 12 months-$42M$16.1B
Free cash flow, 12 months-$33M$20.6B
Earnings per share, 12 months-$1.27$6.59
Revenue growth, year on year115.6%6.1%
Revenue growth a year, past+27.2%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

IMDXJNJ
Margins and returns on capital
Gross margin55.3%67.6%
Operating margin-2,180.1%–
Net margin-2,137.3%16.2%
ROIC–12.4%
ROE–19.7%

Balance sheet

IMDXJNJ
Balance sheet
Cash$11M$17.2B
Total debt$2.0M$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

IMDXJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: IMDX or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Insight Molecular Diagnostics or Johnson & Johnson?

By market value, Johnson & Johnson ($652B) is about 10,285.6 times Insight Molecular Diagnostics ($63M), at today's prices.

How did IMDX and JNJ stock do over the last 10 years?

Since November 22, 2016, IMDX's price moved -98.3% and JNJ's +139.9%. With dividends: IMDX -98.3% (-33.4% a year), JNJ +212.6% (+12.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, IMDX or JNJ?

The dividend yield at today's price is none for Insight Molecular Diagnostics and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Insight Molecular Diagnostics or Johnson & Johnson?

Over the last twelve months, the net margin was -2,137.3% for Insight Molecular Diagnostics and 16.2% for Johnson & Johnson, and the operating margin -2,180.1% and –. Revenue was $2.0M and $99.3B.

Which is the better investment, Insight Molecular Diagnostics or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.